<DOC>
	<DOC>NCT00717067</DOC>
	<brief_summary>The purpose of this study is to assess whether a dosing adjustment is needed in patients with renal impairment.</brief_summary>
	<brief_title>Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks. Body Mass Index (BMI) of approximately 18 to 40 kg/m2 inclusive. Total body weight &gt;50 kg (110 lbs). Male or female subjects between the ages of 18 and 85 years. Subjects with acute renal disease and/or history of renal transplant. Supine BP at Screening ≥160 mm Hg systolic or ≥95 mm Hg diastolic. Supine BP at Screening ≤80 mm Hg systolic or ≤40 mm Hg diastolic.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>maraviroc, pharmacokinetics, renal impairment</keyword>
</DOC>